FDA Panel Votes 8–6 to Clear BPC-157, TB-500 & 4 Peptides for Compounding (July 2026)

On July 23, 2026, at roughly 10:00 AM Eastern, a federal advisory panel did something that almost never happens: it publicly overruled the FDA's own scientists. Then it did it again. By the end of a two-day hearing at the agency's White Oak campus in Silver Spring, Maryland, the Pharmacy Compounding Advisory Committee had voted against the FDA staff's written recommendation six consecutive times.

The result: six popular peptides — including BPC-157 and TB-500 — received committee recommendations for placement on the 503A Bulk Drug Substances list, the regulatory mechanism that allows licensed compounding pharmacies to legally prepare a compound for patients with a prescription. Reporters in the room described an audible gasp when the first vote tally was read aloud.

Here is a plain-English breakdown of what happened, the forces behind it, what the vote actually changes, and what needs to happen before any of it reaches patients.

Key Takeaways

• Six peptides received favorable recommendations for 503A compounding eligibility: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. One peptide — Emideltide (DSIP) — was rejected.
• The votes are advisory and non-binding. The FDA is not legally required to follow the committee's recommendations. Any formal change requires a separate notice-and-comment rulemaking process.
• Rulemaking typically takes 8–12 months — and has taken longer. The FDA has completed this process for only about ten substances since Congress created the list in 1997.
• Interim enforcement discretion is the expected near-term path. Legal analysts widely anticipate the FDA will signal it won't take action against pharmacies compounding the six cleared peptides while rulemaking proceeds.
• A prescription from a licensed physician is still required. These are not supplements or over-the-counter products. A doctor must evaluate you and write an order.
• Insurance will almost certainly not cover it. Compounded drugs are almost universally excluded from coverage. Expect out-of-pocket monthly costs of $80–$350 per peptide, plus an initial consultation fee of $150–$400.
• BPC-157 is not FDA-approved and is not legal over the counter, regardless of how this vote is characterized in media coverage. The committee's recommendation is one step in a longer process.

What Happened: The July 23–24, 2026 PCAC Vote

The FDA's Pharmacy Compounding Advisory Committee (PCAC) convened on July 23 and 24 to evaluate whether seven peptides should be added to the 503A Bulk Drug Substances (Category 1) list.

This list — established by Congress in 1997 under the Federal Food, Drug, and Cosmetic Act — specifies which ingredients licensed compounding pharmacies may legally source from FDA-registered manufacturers and prepare for individual patients under a valid prescription. Placement on the list is the regulatory pathway that turns a peptide from "grey-market compound" into a physician-supervised, pharmacy-dispensed medicine.

The PCAC almost never votes against the FDA staff's written recommendation. At this meeting, it did so six times in two days.

Day One Votes (July 23)

Day Two Votes (July 24)

The committee recommended both the free base and acetate formulations of each cleared peptide.